Treatment with OP449, a novel SET inhibitor, decreases the tumorigenic potential of breast cancer cells, and SET inhibition was proposed as the best therapeutic strategy to activate PP2A – no known inhibitors of CIP2A have been described – as it could be an antitumor strategy to post-translationally target c-MYC. Here, MYC is linked to breast carcinoma.